West Pharmaceutical Services Inc. (NYSE:WST) finished Friday with a subtraction of -$1.04 to close at $421.19, a downside of -0.25 percent. An average of 310,120 shares of common stock have been traded in the last five days. There was a gain of $16.38 in the past week, and it reached a new high 57 times over the past 12 months. The last 20 days have seen an average of 343,535 shares traded, while the 50-day average volume stands at 320,408.
WST stock has decreased by -7.48% in the last month. The company shares reached their 1-month lowest point of $399.16 on 10/13/21. With the stock rallying to its 52-week high on 09/09/21, shares of the company touched a low of $253.85 and a high of $475.35 in 52 weeks. It has reached a new high 54 times so far this year and achieved 48.67% or $137.88 in price. In spite of this, the price is down -11.39% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
43 days have passed since West Pharmaceutical Services Inc. (WST) last reported insider trading activity. Lai Quintin J, who is VP Corp Development & Strategy, most recently acquired $9,672 shares at $460.76 per share on Sep 10. In this transaction, the insider spent $4,456,452. Chief Digital & Trans Officer, Abraham Silji, disposed of 2,171 shares at a price of $335.00 on May 10. The insider now owns more than $727,285 worth of shares. Prior to that, Sr. VP, GC & Corp. Sec. MILLER GEORGE LLOYD went on to Sale 9,000 shares at $296.67 each on Nov 06. An amount of $2,670,041 was transacted.
West Pharmaceutical Services Inc. (WST) has a trailing price-to-earnings (P/E) ratio of 61.55, which compares with the 26.30 for the broader industry and 33.43 for the sector. In the last five years, West Pharmaceutical Services Inc.’s PE ratio has ranged between 75.99 and 32.35. The stock’s beta is 1.00. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 12.43, the price-to-book (PB) ratio at 15.33, and the price-to-cash flow ratio at 134.08.
West Pharmaceutical Services Inc. pays a $0.68 dividend per share annually. It offers a dividend yield of 0.16%. The company has a payout ratio of 9.50%. The company’s most recent quarterly dividend payment took place on Aug. 4, and it was $0.17 a share, without any change from last year. Its dividend has been increased for the last 26 consecutive years with the latest increase dividend $0.01 reported on Thursday October 29 2020.Dividends have grown by 22.64% each year over the last three years.
The quick ratio of West Pharmaceutical Services Inc. for the three months ended June 29 was 2.40, and the current ratio was 3.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.12 and a total debt to equity ratio of 0.13 for the quarter ending June 29. West Pharmaceutical Services Inc.’s EBITDA margin for the year ending June 29 is 24.60%, while its operating margin for the same period stands at 23.90%. Its gross profit as reported stood at $767.8 million compared to revenue of $2.15 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, West Pharmaceutical Services Inc.’s return on assets was 18.80%. For the broader industry, ROE averaged 3.96 over the past year.
For the three-month period that ended June 29, West Pharmaceutical Services Inc. had $251.8 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $187.3 million in the quarter, while revenues of $151.2 million were grew 51.31%. The analyst consensus anticipated West Pharmaceutical Services Inc.’s latest quarter earnings to come in at $1.74 per share, but it turned out to be $2.46, a 41.40% surprise. For the quarter, EBITDA amounted to $240.1 million. Shareholders own equity worth $73.98 million.
From a technical analysis perspective, let’s take a brief look at West Pharmaceutical Services Inc. (WST) price momentum. RSI 9-day as of the close on 22 October was 54.92%, suggesting the stock is Neutral, with historical volatility in this time frame at 15.84%.
As of today, WST’s price is $416.86 +4.05% or $16.38 from its 5-day moving average. WST is currently trading -7.86% lower than its 20-day SMA and +26.19% higher than its 100-day SMA. However, the stock’s current price level is -1.99% below the SMA50 and +38.52% above the SMA200.
The stochastic %K and %D were 80.62% and 63.53%, respectively, and the average true range (ATR) was 9.59. With the 14-day stochastic at 85.92% and the average true range at 9.87, the RSI (14) stands at 49.71%. The stock has reached 8.01 on the 9-day MACD Oscillator while the 14-day reading was at 8.11.
KeyBanc Capital Markets launched coverage on West Pharmaceutical Services Inc. (NYSE: WST) in its analyst report released on November 10, 2020. The firm assigned the stock a an Overweight rating. The consensus rating for West Pharmaceutical Services Inc. (WST) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell WST, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 4 others rate it as a “buy”.